
William A Hall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12116672/publications.pdf Version: 2024-02-01



ΛλητιαΜ Α Ηστι

#	Article	IF	CITATIONS
1	Online adaptive MR-guided stereotactic radiotherapy for unresectable malignancies in the upper abdomen using a 1.5T MR-linac. Acta Oncológica, 2022, 61, 111-115.	1.8	26
2	Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 2246-2256.	1.5	29
3	The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?. Clinical and Translational Radiation Oncology, 2021, 28, 124-128.	1.7	4
4	Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Frontiers in Oncology, 2021, 11, 628155.	2.8	27
5	Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. American Journal of Surgery, 2021, 222, 10-17.	1.8	41
6	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2021, 39, 3773-3777.	1.6	17
7	Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Annals of Surgery, 2020, 271, 740-747.	4.2	127
8	Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?. Journal of Gastrointestinal Surgery, 2020, 24, 235-242.	1.7	6
9	Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. Surgery, 2020, 168, 440-447.	1.9	15
10	Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Practical Radiation Oncology, 2020, 10, e495-e507.	2.1	50
11	Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 460.	2.8	20
12	Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. Radiation Oncology, 2019, 14, 114.	2.7	34
13	Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surgery, 2019, 166, 277-285.	1.9	40
14	Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2019, 9, 322-332.	2.1	121
15	Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy. JAMA Oncology, 2019, 5, 664.	7.1	40
16	A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2018, 268, 610-619.	4.2	58
17	Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer, 2017, 123, 3486-3493.	4.1	103
18	Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 2325-2332.	1.6	490

WILLIAM A HALL

#	Article	IF	CITATIONS
19	Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas. World Journal of Gastrointestinal Oncology, 2016, 8, 358.	2.0	12
20	CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer. Cancer Research, 2014, 74, 2677-2687.	0.9	34
21	Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. Cancer, 2014, 120, 499-506.	4.1	39
22	The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2014, 5, 77-85.	1.4	10
23	The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. Cancer, 2013, 119, 2350-2357.	4.1	13
24	Pronecrotic mixed lineage kinase domainâ€like protein expression is a prognostic biomarker in patients with earlyâ€stage resected pancreatic adenocarcinoma. Cancer, 2013, 119, 3148-3155.	4.1	105